Trial Profile
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2021
Price :
$35
*
At a glance
- Drugs Oplunofusp (Primary)
- Indications Parainfluenza virus infections
- Focus Therapeutic Use
- Sponsors Ansun Biopharma
- 11 Feb 2021 Primary endpoint (Clinical Stability survival at day 45) has not been met as per results published in the Clinical Infectious Diseases
- 11 Feb 2021 Results published in the Clinical Infectious Diseases
- 07 Oct 2018 Results presented at the IDWeek 2018